Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

NRX Pharmaceuticals (NRXP) EBITDA Margin (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed EBITDA Margin for 2 consecutive years, with 876.3% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 876.3% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1802.53% through Dec 2025, down 1249644.0% year-over-year, with the annual reading at 1323.59% for FY2025, N/A changed from the prior year.
  • EBITDA Margin for Q4 2025 was 876.3% at NRX Pharmaceuticals, up from 2433.88% in the prior quarter.
  • The five-year high for EBITDA Margin was 2607.83% in Q1 2024, with the low at 2433.88% in Q3 2025.